Myriad Genetics to present new ASCO-GU 2026 data on Precise MRD, Prolaris, and MyRisk tests

Reuters

Feb 24

Myriad Genetics to present new ASCO-GU 2026 data on Precise MRD, Prolaris, and MyRisk tests

Myriad Genetics Inc. announced that six abstracts will be presented at the 2026 ASCO Genitourinary Cancers Symposium (Feb. 26–28) on its Precise MRD molecular residual disease test, Prolaris prostate cancer prognostic test, and MyRisk hereditary cancer test. The presentations include interim and preliminary results from studies evaluating whole-genome sequencing–based ctDNA detection in urothelial cancer and renal cell carcinoma, a phase I/II trial (CONSOLIDATE) combining radiotherapy with enfortumab vedotin in locally advanced bladder cancer with paired ctDNA and utDNA analyses, an individual participant data meta-analysis of 14 Prolaris studies involving more than 8,000 patients, and an analysis of germline variant prevalence by Gleason score and NCCN risk grouping in localized prostate cancer. Results have not yet been presented and are scheduled for presentation at the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240900PRIMZONEFULLFEED9659575) on February 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2613875717"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613875717\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613875717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613875717","market":"us","top_or_hot":-1,"title":"Myriad Genetics to present new ASCO-GU 2026 data on Precise MRD, Prolaris, and MyRisk tests","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Myriad Genetics to present new ASCO-GU 2026 data on Precise MRD, Prolaris, and MyRisk tests\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Myriad Genetics Inc. announced that six abstracts will be presented at the 2026 ASCO Genitourinary Cancers Symposium (Feb. 26–28) on its Precise MRD molecular residual disease test, Prolaris prostate cancer prognostic test, and MyRisk hereditary cancer test. The presentations include interim and preliminary results from studies evaluating whole-genome sequencing–based ctDNA detection in urothelial cancer and renal cell carcinoma, a phase I/II trial (CONSOLIDATE) combining radiotherapy with enfortumab vedotin in locally advanced bladder cancer with paired ctDNA and utDNA analyses, an individual participant data meta-analysis of 14 Prolaris studies involving more than 8,000 patients, and an analysis of germline variant prevalence by Gleason score and NCCN risk grouping in localized prostate cancer. Results have not yet been presented and are scheduled for presentation at the meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240900PRIMZONEFULLFEED9659575) on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics to present new ASCO-GU 2026 data on Precise MRD, Prolaris, and MyRisk tests</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics to present new ASCO-GU 2026 data on Precise MRD, Prolaris, and MyRisk tests\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Myriad Genetics to present new ASCO-GU 2026 data on Precise MRD, Prolaris, and MyRisk tests\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Myriad Genetics Inc. announced that six abstracts will be presented at the 2026 ASCO Genitourinary Cancers Symposium (Feb. 26–28) on its Precise MRD molecular residual disease test, Prolaris prostate cancer prognostic test, and MyRisk hereditary cancer test. The presentations include interim and preliminary results from studies evaluating whole-genome sequencing–based ctDNA detection in urothelial cancer and renal cell carcinoma, a phase I/II trial (CONSOLIDATE) combining radiotherapy with enfortumab vedotin in locally advanced bladder cancer with paired ctDNA and utDNA analyses, an individual participant data meta-analysis of 14 Prolaris studies involving more than 8,000 patients, and an analysis of germline variant prevalence by Gleason score and NCCN risk grouping in localized prostate cancer. Results have not yet been presented and are scheduled for presentation at the meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240900PRIMZONEFULLFEED9659575) on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL7rRGyj:1","article_id":"2613875717","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613875717","pubTimestamp":1771941651,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Myriad Genetics Inc. announced that six abstracts will be presented at the 2026 ASCO Genitourinary Cancers Symposium  on its Precise MRD molecular residual disease test, Prolaris prostate cancer prognostic test, and MyRisk hereditary cancer test. The presentations include interim and preliminary results from studies evaluating whole-genome sequencing–based ctDNA detection in urothelial cancer and renal cell carcinoma, a phase I/II trial  combining radiotherapy with enfortumab vedotin in locally advanced bladder cancer with paired ctDNA and utDNA analyses, an individual participant data meta-analysis of 14 Prolaris studies involving more than 8,000 patients, and an analysis of germline variant prevalence by Gleason score and NCCN risk grouping in localized prostate cancer. Results have not yet been presented and are scheduled for presentation at the meeting.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Myriad Genetics将展示有关精确MRD、Prolaris和MyRisk测试的新ASCO-GU 2026数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":0.9,"NDAQ":0.9},"content_text":"Myriad Genetics to present new ASCO-GU 2026 data on Precise MRD, Prolaris, and MyRisk tests\n    \n\n        Myriad Genetics Inc. announced that six abstracts will be presented at the 2026 ASCO Genitourinary Cancers Symposium (Feb. 26–28) on its Precise MRD molecular residual disease test, Prolaris prostate cancer prognostic test, and MyRisk hereditary cancer test. The presentations include interim and preliminary results from studies evaluating whole-genome sequencing–based ctDNA detection in urothelial cancer and renal cell carcinoma, a phase I/II trial (CONSOLIDATE) combining radiotherapy with enfortumab vedotin in locally advanced bladder cancer with paired ctDNA and utDNA analyses, an individual participant data meta-analysis of 14 Prolaris studies involving more than 8,000 patients, and an analysis of germline variant prevalence by Gleason score and NCCN risk grouping in localized prostate cancer. Results have not yet been presented and are scheduled for presentation at the meeting.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240900PRIMZONEFULLFEED9659575) on February 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}